University VC Fund Invests in BioReact AI

- BioReact was co-founded by CEO Mitchell Castetter, who has a background in biotech sales, and CTO Joanna Lipinski, who brings over 20 years of experience in biotech software development and data platforms. The founding team's vision stemmed from observing that scientists were using modern biology techniques but relying on outdated data tools like spreadsheets, which slowed down innovation. - The company's platform addresses the challenge of fragmented data in bioprocessing by unifying offline and online data from various lab instruments. This allows scientists, without needing coding expertise, to automatically align and visualize complex datasets in seconds, a process that could otherwise take hours of manual work. - BioReact's core technology uses proprietary AI algorithms to model and simulate thousands of bioprocess experiments. By analyzing parameters such as temperature, pH, and media composition, the platform helps scientists identify optimal conditions to increase yields and shorten development cycles for products in biopharma, synthetic biology, and cultured meat. - The company has adopted a freemium model to accelerate adoption, allowing researchers and startups to use the platform for up to 10 experiments for free. As of mid-2025, the platform had attracted over 600 monthly active users and processed more than 20 million data points. - Prior to the Hurricane Ventures investment, Indianapolis-based BioReact raised $120K in a seed round from investors including Techstars and New Stack Ventures. - Hurricane Ventures was launched in April 2023 as the University of Tulsa's venture capital fund, aiming to invest in early-stage companies with connections to the university. BioReact marks the 12th company to receive investment from the fund.